Steven Glazer is a well renowned clinical expert and biotech entrepreneur who has a strong record of bringing oncology products forward into clinical development. Steven will be supporting MonTa in the clinical development of MBS8 which is planned to enter clinical trial by the end of 2020. The board and management of MonTa Biosciences are very honoured to have such strong clinical expert to join the management team and contribute with years of experience in clinical development of new oncology technologies.
